Telomere Maintenance Crucial in Overcoming Cancer Drug Resistance

Strategic Insights -

Researchers at Wayne State University have made significant discoveries about the role of telomeres and telomerase in cancer drug resistance. Their study, published in the Journal of Chemotherapy, found that changes in telomerase activity and/or telomere length are key factors in the development of resistance to cancer drugs. The study assessed telomere lengths and telomerase activity in human tumor cell lines that had developed resistance to several anticancer agents, including vindesine, gemcitabine, and cisplatin. The results suggest that telomere maintenance should be considered in efforts to overcome drug resistance and optimize the use of telomere-based therapeutics.

Key Takeaways:

  • The study found that changes in telomerase activity and/or telomere length are associated with cancer drug resistance.
  • The researchers discovered that several drug-specific resistance patterns emerged in the studied cell lines, but these were not related to drug efflux pump expression, glutathione levels, or polyadenosine-ribose polymerase (PARP) cleavage.
  • The study provides evidence that telomere maintenance should be taken into consideration in efforts to overcome drug resistance and optimize the use of telomere-based therapeutics.
  • The researchers evaluated the resistant clones in comparison to their parental lines and found complex patterns of cross-resistance to other cytotoxic agents.
  • The study was conducted on a panel of human tumor cell lines resistant to vindesine, gemcitabine, and cisplatin, including lung cancer, renal cancer, and ovarian cancer cell lines.
  • The researchers assessed telomere lengths and telomerase activity in addition to drug efflux pump expression, glutathione levels, and PARP cleavage in the resistant clones.

Statistics:

  • The study included a panel of human tumor cell lines, including 2 lung cancer cell lines resistant to vindesine, 1 renal cancer cell line resistant to gemcitabine, 1 ovarian cancer cell line resistant to gemcitabine, and 1 cell line resistant to cisplatin.
  • The resistant clones were compared to their parental lines and evaluated for cross-resistance to other cytotoxic agents.
  • The researchers found several drug-specific resistance patterns and complex patterns of cross-resistance in the studied cell lines.

Sources:

  • Smith, V., et al. (2009). Telomerase Activity and Telomere Length in Human Tumor Cells with Acquired Resistance to Anticancer Agents. Journal of Chemotherapy, 21(5), 542-549.
  • Wayne State University. (n.d.). Wayne State University. Retrieved from
  • Journal of Chemotherapy. (n.d.). Journal of Chemotherapy. Retrieved from